Glutathione accelerates osteoclast differentiation and inflammatory bone destruction

Hirofumi Fujita, Masahiko Ochi, Mitsuaki Ono, Eriko Aoyama, Tetsuya Ogino, Yoichi Kondo, Hideyo Ohuchi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chronic inflammation associated with bone tissues often destructs bones, which is essentially performed by osteoclasts in the presence of immunoregulatory molecules. Hence, regulating osteoclastogenesis is crucial to develop therapeutics for bone-destructive inflammatory diseases. It is believed that reactive oxygen species (ROS) are involved in receptor activator of NF-κB (RANK) ligand (RANKL)-induced osteoclast differentiation, and, therefore, glutathione (GSH), the most abundant endogenous antioxidant, suppresses osteoclast differentiation and bone resorption by RANKL. Interestingly, GSH also contributes to inflammatory responses, and the effects of GSH on osteoclast differentiation and bone destruction under inflammatory conditions have not yet been determined. Here, we investigated how GSH affects inflammatory cytokine-stimulated osteoclast differentiation in vitro and in a mouse model of inflammatory bone destruction. We found that GSH significantly promoted TNFα-stimulated osteoclast formation, while an inhibitor of GSH synthesis, buthionine sulfoximine, suppressed it. GSH facilitated the nuclear localisation of the nuclear factor of activated T cells c1 (NFATc1) protein, a master regulator of osteoclastogenesis, as well as the expression of osteoclast marker genes in a dose-dependent manner. N-acetylcysteine, a substrate of GSH synthesis, also stimulated osteoclast formation and NFATc1 nuclear localisation. GSH did not suppress cell death after osteoclast differentiation. In mouse calvaria injected with lipopolysaccharide, GSH treatment resulted in a fivefold increase in the osteolytic lesion area. These results indicate that GSH accelerates osteoclast differentiation and inflammatory bone destruction, suggesting GSH appears to be an important molecule in the mechanisms responsible for inflammatory bone destruction by osteoclasts.

Original languageEnglish
JournalFree Radical Research
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Osteoclasts
Glutathione
Bone
Bone and Bones
RANK Ligand
NFATC Transcription Factors
Osteogenesis
Buthionine Sulfoximine
Molecules
Acetylcysteine
Cell death
Bone Resorption
Skull
Lipopolysaccharides
Reactive Oxygen Species
Cell Death
Antioxidants
Genes
Tissue
Cytokines

Keywords

  • Bone destruction
  • glutathione
  • inflammation
  • NFATc1
  • osteoclastogenesis

ASJC Scopus subject areas

  • Biochemistry

Cite this

Glutathione accelerates osteoclast differentiation and inflammatory bone destruction. / Fujita, Hirofumi; Ochi, Masahiko; Ono, Mitsuaki; Aoyama, Eriko; Ogino, Tetsuya; Kondo, Yoichi; Ohuchi, Hideyo.

In: Free Radical Research, 01.01.2019.

Research output: Contribution to journalArticle

@article{5ff9397fdc6b44f1bc94c8d8eebcf9e2,
title = "Glutathione accelerates osteoclast differentiation and inflammatory bone destruction",
abstract = "Chronic inflammation associated with bone tissues often destructs bones, which is essentially performed by osteoclasts in the presence of immunoregulatory molecules. Hence, regulating osteoclastogenesis is crucial to develop therapeutics for bone-destructive inflammatory diseases. It is believed that reactive oxygen species (ROS) are involved in receptor activator of NF-κB (RANK) ligand (RANKL)-induced osteoclast differentiation, and, therefore, glutathione (GSH), the most abundant endogenous antioxidant, suppresses osteoclast differentiation and bone resorption by RANKL. Interestingly, GSH also contributes to inflammatory responses, and the effects of GSH on osteoclast differentiation and bone destruction under inflammatory conditions have not yet been determined. Here, we investigated how GSH affects inflammatory cytokine-stimulated osteoclast differentiation in vitro and in a mouse model of inflammatory bone destruction. We found that GSH significantly promoted TNFα-stimulated osteoclast formation, while an inhibitor of GSH synthesis, buthionine sulfoximine, suppressed it. GSH facilitated the nuclear localisation of the nuclear factor of activated T cells c1 (NFATc1) protein, a master regulator of osteoclastogenesis, as well as the expression of osteoclast marker genes in a dose-dependent manner. N-acetylcysteine, a substrate of GSH synthesis, also stimulated osteoclast formation and NFATc1 nuclear localisation. GSH did not suppress cell death after osteoclast differentiation. In mouse calvaria injected with lipopolysaccharide, GSH treatment resulted in a fivefold increase in the osteolytic lesion area. These results indicate that GSH accelerates osteoclast differentiation and inflammatory bone destruction, suggesting GSH appears to be an important molecule in the mechanisms responsible for inflammatory bone destruction by osteoclasts.",
keywords = "Bone destruction, glutathione, inflammation, NFATc1, osteoclastogenesis",
author = "Hirofumi Fujita and Masahiko Ochi and Mitsuaki Ono and Eriko Aoyama and Tetsuya Ogino and Yoichi Kondo and Hideyo Ohuchi",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/10715762.2018.1563782",
language = "English",
journal = "Free Radical Research",
issn = "1071-5762",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Glutathione accelerates osteoclast differentiation and inflammatory bone destruction

AU - Fujita, Hirofumi

AU - Ochi, Masahiko

AU - Ono, Mitsuaki

AU - Aoyama, Eriko

AU - Ogino, Tetsuya

AU - Kondo, Yoichi

AU - Ohuchi, Hideyo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Chronic inflammation associated with bone tissues often destructs bones, which is essentially performed by osteoclasts in the presence of immunoregulatory molecules. Hence, regulating osteoclastogenesis is crucial to develop therapeutics for bone-destructive inflammatory diseases. It is believed that reactive oxygen species (ROS) are involved in receptor activator of NF-κB (RANK) ligand (RANKL)-induced osteoclast differentiation, and, therefore, glutathione (GSH), the most abundant endogenous antioxidant, suppresses osteoclast differentiation and bone resorption by RANKL. Interestingly, GSH also contributes to inflammatory responses, and the effects of GSH on osteoclast differentiation and bone destruction under inflammatory conditions have not yet been determined. Here, we investigated how GSH affects inflammatory cytokine-stimulated osteoclast differentiation in vitro and in a mouse model of inflammatory bone destruction. We found that GSH significantly promoted TNFα-stimulated osteoclast formation, while an inhibitor of GSH synthesis, buthionine sulfoximine, suppressed it. GSH facilitated the nuclear localisation of the nuclear factor of activated T cells c1 (NFATc1) protein, a master regulator of osteoclastogenesis, as well as the expression of osteoclast marker genes in a dose-dependent manner. N-acetylcysteine, a substrate of GSH synthesis, also stimulated osteoclast formation and NFATc1 nuclear localisation. GSH did not suppress cell death after osteoclast differentiation. In mouse calvaria injected with lipopolysaccharide, GSH treatment resulted in a fivefold increase in the osteolytic lesion area. These results indicate that GSH accelerates osteoclast differentiation and inflammatory bone destruction, suggesting GSH appears to be an important molecule in the mechanisms responsible for inflammatory bone destruction by osteoclasts.

AB - Chronic inflammation associated with bone tissues often destructs bones, which is essentially performed by osteoclasts in the presence of immunoregulatory molecules. Hence, regulating osteoclastogenesis is crucial to develop therapeutics for bone-destructive inflammatory diseases. It is believed that reactive oxygen species (ROS) are involved in receptor activator of NF-κB (RANK) ligand (RANKL)-induced osteoclast differentiation, and, therefore, glutathione (GSH), the most abundant endogenous antioxidant, suppresses osteoclast differentiation and bone resorption by RANKL. Interestingly, GSH also contributes to inflammatory responses, and the effects of GSH on osteoclast differentiation and bone destruction under inflammatory conditions have not yet been determined. Here, we investigated how GSH affects inflammatory cytokine-stimulated osteoclast differentiation in vitro and in a mouse model of inflammatory bone destruction. We found that GSH significantly promoted TNFα-stimulated osteoclast formation, while an inhibitor of GSH synthesis, buthionine sulfoximine, suppressed it. GSH facilitated the nuclear localisation of the nuclear factor of activated T cells c1 (NFATc1) protein, a master regulator of osteoclastogenesis, as well as the expression of osteoclast marker genes in a dose-dependent manner. N-acetylcysteine, a substrate of GSH synthesis, also stimulated osteoclast formation and NFATc1 nuclear localisation. GSH did not suppress cell death after osteoclast differentiation. In mouse calvaria injected with lipopolysaccharide, GSH treatment resulted in a fivefold increase in the osteolytic lesion area. These results indicate that GSH accelerates osteoclast differentiation and inflammatory bone destruction, suggesting GSH appears to be an important molecule in the mechanisms responsible for inflammatory bone destruction by osteoclasts.

KW - Bone destruction

KW - glutathione

KW - inflammation

KW - NFATc1

KW - osteoclastogenesis

UR - http://www.scopus.com/inward/record.url?scp=85062478743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062478743&partnerID=8YFLogxK

U2 - 10.1080/10715762.2018.1563782

DO - 10.1080/10715762.2018.1563782

M3 - Article

C2 - 30741054

AN - SCOPUS:85062478743

JO - Free Radical Research

JF - Free Radical Research

SN - 1071-5762

ER -